This is a major breakthrough. The European Medicines Agency (EMA) has just released their decision to approve Voxzogo (vosoritide) for the treatment of achondroplasia in children two year-old and older until their growth plates close.
This approval comes not far behind the recent decision by the French health authority to grant temporary approval for vosoritide in children 5+ years of age in July. You can read the French authorization and prescription protocol here (in French).
You can read the Biomarin's press release here.
Great news for so many children in the world!